Osteoarthritis (OA) is a painful, complex disease that affects millions of people worldwide. There is currently no disease-modifying therapy for OA, and existing drugs to treat symptoms of OA are ...
The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with neuropathic corneal pain, according to a press release from Okyo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results